Compare Amphastar Pharmaceuticals Inc (AMPH) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs DuPont de Nemours Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.44 (market cap $863.95M), while DuPont de Nemours Inc trades at $143.54 (market cap $19.12B). The key difference: DuPont de Nemours Inc is far larger — about 22.1× Amphastar Pharmaceuticals Inc's market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DD | |
|---|---|---|
Market Cap | $863.95M | $19.12B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $154.59 |
52-Week Low | $16.87 | $87.72 |
Enterprise Value | $1.26B | $20.50B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
